信迪利单抗联合化疗新辅助治疗Ⅲ期非小细胞肺癌的疗效  

Efficacy of sintilimab combined with chemotherapy neoadjuvant in the treatment of stageⅢnon-small cell lung cancer

作　　者：郑家雷 莫缓缓 赵艳[2] 耿阳 陶涛[3] ZHENG Jialei;MO Huanhuan;ZHAO Yan;GENG Yang;TAO Tao(Department of Oncology,First Affiliated Hospital of Bengbu Medical College,Bengbu 233003,China;Department of Pathology,First Affiliated Hospital of Bengbu Medical College,Bengbu 233003,China;Department of Chest Surgery,First Affiliated Hospital of Bengbu Medical College,Bengbu 233003,China)

机构地区：[1]蚌埠医学院第一附属医院肿瘤内科,安徽蚌埠233003 [2]蚌埠医学院第一附属医院病理科,安徽蚌埠233003 [3]蚌埠医学院第一附属医院胸外科,安徽蚌埠233003

出　　处：《分子影像学杂志》2023年第5期811-816,共6页Journal of Molecular Imaging

基　　金：安徽高校自然科学研究项目(KJ2020A0575)。

摘　　要：目的评价信迪利单抗联合化疗新辅助治疗Ⅲ期非小细胞肺癌的近期疗效和安全性。方法分析2021年1月~2023年7月我院26例使用信迪利单抗联合化疗新辅助治疗Ⅲ期非小细胞肺癌患者的临床资料,评估患者影像学和病理学效果并观察免疫联合化疗新辅助治疗的安全性。结果23例患者完成根治性手术治疗,手术切除率88.5%,22例R0切除,R0切除率95.7%。影像学结果客观缓解率为92.3%(完全缓解率为11.5%,部分缓解为80.8%);疾病控制率为96.1%,病理完全缓解率为26.1%,主要病理缓解率为60.9%。常见不良反应:白细胞下降(42.3%)、外周神经毒性(46.2%)、消化道不良反应(23.1%)、甲状腺功能异常(11.5%),3级以上不良反应发生率约为7.7%,未发生严重免疫相关不良反应。结论信迪利单抗联合化疗新辅助治疗Ⅲ期非小细胞肺癌的疗效显著,R0切除率高,病理缓解率高,安全性可耐受。Objective To evaluate the short-term efficacy and safety of sintilimab combined with chemotherapy neoadjuvant in the treatment of stageⅢnon-small cell lung cancer.Methods The clinical data of 26 patients with stageⅢnon-small cell lung cancer treated with Sintilimab combined with chemotherapy neoadjuvant therapy in our hospital from January 2021 to July 2023 were analyzed.The imaging and pathological effects of the patients were evaluated.The safety of immunotherapy combined with chemotherapy neoadjuvant therapy was observed.Results Twenty-three patients completed radical surgery with a surgical resection rate of 88.5%,and 22 patients underwent R0 resection with a R0 resection rate of 95.7%.Objective response rate of imaging results was 92.3%(complete response rate was 11.5%,partial response rate was 80.8%).The disease control rate was 96.1%,the pathological complete response rate was 26.1%,and the main pathological response rate was 60.9%.Common adverse reactions:The incidence of leukopenia was 42.3%,peripheral neurotoxicity was 46.2%,gastrointestinal adverse reactions were 23.1%,thyroid dysfunction was 11.5%,and the incidence of grade 3 or above adverse reactions was about 7.7%.No serious immune related adverse reactions had occurred.Conclusion The combination of sintilimab and neoadjuvant chemotherapy has a significant therapeutic effect on stageⅢnon-small cell lung cancer,with a high R0 resection rate,high pathological response rate,and tolerable safety.

关 键 词：信迪利单抗 化疗 新辅助治疗 Ⅲ期非小细胞肺癌 疗效 

分 类 号：R730.44[医药卫生—肿瘤] R734.2[医药卫生—临床医学]